Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMMAL3I)

• Drug Name: SB-415286 Drug Info
• Synonyms: SB 415286; 264218-23-7; SB-415286; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855
• Cross-matching ID:
  PubChem CID: 4210951
  ChEBI ID: CHEMBL322970
  CAS Number: CAS 264218-23-7
  TTD Drug ID: D0N4WB

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Rheumatoid arthritis	2.27	0.00e+0	78/93 (83.87%)	CXCL8;MMP3;CXCL5;...
Ribosome biogenesis in eukaryotes	2.04	0.00e+0	52/108 (48.15%)	GNL3;DKC1;NVL;...
Intestinal immune network for IgA production	1.97	6.55e-3	38/48 (79.17%)	ITGA4;HLA-DQA1;CD40;...
IL-17 signaling pathway	1.97	4.91e-3	84/94 (89.36%)	CXCL8;MMP3;CXCL5;...
TNF signaling pathway	1.84	2.16e-2	103/112 (91.96%)	MMP3;CXCL5;TNFAIP3;...
Oxidative phosphorylation	1.78	3.27e-2	93/133 (69.92%)	NDUFA4L2;CYC1;ATP6V0E2;...
Citrate cycle (TCA cycle)	1.78	3.37e-2	30/30 (100%)	DLD;SUCLA2;IDH2;...
Viral protein interaction with cytokine and cytokine re...	1.77	3.07e-2	84/100 (84%)	CXCL13;CXCL14;CXCL8;...
Toxoplasmosis	1.76	2.95e-2	103/112 (91.96%)	CYCS;PPIF;LAMC2;...
Proteasome	1.74	3.34e-2	44/46 (95.65%)	PSMA3;PSMB9;POMP;...
Steroid biosynthesis	-2.03	0.00e+0	19/20 (95%)	CYP51A1;LSS;SC5D;...
FoxO signaling pathway	-2.04	0.00e+0	118/131 (90.08%)	PRKAA1;KRAS;BRAF;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Fibrocystic breast disease

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A (Parent)	CVCL_0598	Homo sapiens	1.11uM - 10uM	3H, 6H, 12H, 24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼